Cytokinetics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 7 Sell calls were actually followed by a +4% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -27.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 100.0% | Better than 99% |
| Operating margin | -695.4% | Better than 3% |
| Net margin | -891.6% | Better than 3% |
| Return on equity | -572.1% | Better than 1% |
| Return on invested capital | -60.4% | Better than 5% |
Momentum D+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -33.9% | Better than 14% |
| 6-month return | -34.0% | Better than 15% |
| 12-month return (ex latest month) | -4.8% | Better than 27% |
| Distance below 52-week high | 42.5% | Better than 26% |
Financial Health C+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.5x | Better than 84% |
| Debt to assets | 90.2% | Better than 2% |
| Interest coverage | -6.6x | Better than 15% |
| Free cash flow / net income | 215.1% | Better than 79% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 93.8% | Better than 76% |
| Upside to average target | 111.3% | Better than 86% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 51.46
- Open
- 51.27
- Day range
- 50.60 - 53.45
- Avg price
- 51.42
- Volume
- 1.43M
- Turnover
- 73.51M
- Turnover ratei
- 1.03%
- Volume ratioi
- 0.81
- Amplitudei
- 5.54%
- 52-week rangei
- 50.32 - 88.31
Valuation
- P/Ei
- -7.76
- P/E (TTM)i
- -8.44
- P/Bi
- -22.02
- EPSi
- -6.54
- Book value / shi
- -2.31
- Net profit
- -911.04M
- Net assets
- -321.23M
Share structure
- Market cap
- 7.07B
- Float capi
- 7.05B
- Shares out
- 139.30M
- Float sharesi
- 138.78M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
42.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-28.46M net over the window
Short interest
- Shares short
- 17.93M
- % of floati
- 12.90%
- Days to coveri
- 14.15
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Cytokinetics (CYTK)?
Cytokinetics last traded at 50.78. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Cytokinetics's market cap?
About 7.07B.
What is the P/E ratio of Cytokinetics?
The trailing twelve-month P/E is -8.44. The Valuation tab shows it against the stock's own five-year range.
Does Cytokinetics pay a dividend?
Cytokinetics does not currently pay a regular dividend.
Is Cytokinetics a buy according to analysts?
The consensus of 16 analysts is a Buy rating, with an average 12-month price target of 107.29, which implies 111.3% upside from the current price. This is not investment advice.
What is Cytokinetics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Cytokinetics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.
Cytokinetics discussion 0 comments